Sex steroids and bone: current perspectives
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Although the process of bone remodelling or its control has not yet been fully elucidated there is, at present, sufficient information available to conclude that ovarian steroids (estrogens, androgens, progesterone) play an essential role in skeletal homeostasis. The mechanism of action of sex steroids on the skeleton is still not entirely clear, but it has traditionally included indirect effects on systemic hormones that regulate calcium balance and a direct receptor-mediated action. More recently, changes in cytokine production within the bone marrow, as well as pro-apoptotic and anti-apoptotic effects in the osteoblastic cells, have been proposed as new perspectives on the cellular and molecular mechanisms by which sex steroids influence adult bone homeostasis. Mechanical loading, when combined with estrogens or androgens, results in a greater osteogenic response than either condition separately. Women are especially at risk for osteoporosis if they have had a premature or surgical menopause and have not received hormone replacement therapy (HRT). Other reproductive factors that can help to identify women with osteopenia and emphasize the role of sex steroids in preserving bone mass in premenopausal women include: age at menarche, menstrual history and irregularities (including those associated with excessive exercise), age at menopause, previous hysterectomy, hyperprolactinaemia, anorexia nervosa, scoliosis, ovarian dysgenesis, pregnancy and lactation, and pharmacological ovarian suppression. The prevention of osteoporosis starts with the onset of the menarche. A combination of exercise, appropriate nutrition and a healthy lifestyle all maximize bone mineral accrual and result in optimal peak bone mass; normal ovarian function is essential to this process. Unfortunately, many women actually become aware of the need for osteoporosis prevention much later in life, usually after they have already become menopausal. HRT, however, has important limitations for prevention of fractures in post-menopausal women. Future perspectives for treatment of osteoporosis include androgen therapy and anabolic agents. Specifically, synthetic ligands of the estrogen receptor that can evoke the non-genotrophic but not the genotrophic signal of the receptor may be bone anabolic agents, as opposed to natural estrogens or selective estrogen receptor modulators that are anti-resorptive agents. The same ligands may circumvent the side effects associated with conventional HRT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602 · cited 4×
“, 2001; Rosen and Bilezikian, 2001) strongly support this contention by showing that the anabolic property of parathyroid hormone restores bone mineral density in the normal range and prevents bone fractures to levels much greater than those seen with anti-resorptive agents (Neer et al., 2001).”
BackgroundResultInfluentialCummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277 · cited 1×
“Clinical trials of bisphosphonates have found an effect on the risk of fracture in women with osteoporosis, but not in women with normal bone density (Cummings et al., 1998; McClung et al., 2001).”
BackgroundEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918 · cited 1×
“Clinical trials of bisphosphonates have found an effect on the risk of fracture in women with osteoporosis, but not in women with normal bone density (Cummings et al., 1998; McClung et al., 2001).”
BackgroundSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990 · cited 3×
“…in the risk of fracture and colorectal cancer are outweighed by increases in the risk of coronary heart disease, stroke, pulmonary embolism, breast cancer and biliary tract surgery (Simon et al., 2001; Nelson et al., 2002b; Writing Group for the Women's Health Initiative Investigators, 2002).”
BackgroundResultBurger, H. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02985-0 · Cited by 771 · cited 4×
“The concept of an androgen de®ciency syndrome in women is a relatively old one, although it has attracted a substantial increase in attention during recent years (Burger, 2002b).”
BackgroundInfluentialBachmann, G., Bancroft, J., Braunstein, G., Burger, H., Davis, S., Dennerstein, L., Goldstein, I., Guay, A., Leiblum, S., Lobo, R., et al. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02969-2 · Cited by 444
Bone mineral density after resumption of menses in amenorrheic athletes
Drinkwater, B. L. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380030082032 · Cited by 386 · cited 1×
“It seems likely that it is the reduction in sex steroids which is associated with reduced bone mass and thus, the return of menses (usually following a reduction in exercise) results in a degree of recovery (Drinkwater et al., 1986).”
BackgroundZborowski, J. V., Cauley, J. A., Talbott, E. O., Guzick, D. S., & Winters, S. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6902 · Cited by 89 · cited 1×
“Clinical evidence of androgen effects on bone mass comes from women with hirsutism, polycystic ovarian disease and secreting ovarian tumours who often have increased bone mineral density (Gregoriou et al., 2000; Zborowski et al., 2000; Castelo-Branco et al., 2003).”
Background
Cited by
Liu, S. L., & Lebrun, C. M. (2006) · British Journal of Sports Medicine · doi:10.1136/bjsm.2005.020065 · Cited by 150
“However, oestrogen also mediates indirect actions on bone through effects on hormones, such as calcitonin and parathyroid hormone, and on cytokines and growth factors.”
BackgroundBone Health in Athletes: The Role of Exercise, Nutrition, and Hormones
Goolsby, M. A., & Boniquit, N. (2017) · Sports Health: A Multidisciplinary Approach · doi:10.1177/1941738116677732 · Cited by 136
“Estrogen acts on osteoblasts and osteoclasts in a receptor-mediated fashion and has indirect effects on other hormones, including calcitonin, parathyroid hormone, cytokines, and growth factors.(5,60) Adolescence is a particularly crucial period for skeletal development.”
BackgroundMohd Effendy, N., Mohamed, N., Muhammad, N., Naina Mohamad, I., & Shuid, A. N. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/125761 · Cited by 55
“Androgens are the most abundant circulating sex steroids in both men and women that modulate bone remodelling cycle through direct androgenic activity via androgen receptor (AR) or indirect action through aromatization to estrogens [41].”
Background
Metadata
- Authors
- Balasch, J.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05-01
- Volume
- 9
- Issue
- 3
- Pages
- 207-222
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2148960457
- Cited by
- 116
- References
- 10
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.